Ocular Side Effects of Antibody-Drug Conjugates

Antibody-drug conjugates (ADCs) are new chemotherapeutic agents that can have significant ocular side effects. Drs. Meghan Berkenstock, Lauren Dalvin, and Stella Kim review this new class of drugs and how they can affect the eye, providing essential tips for what to look for, when to screen, and how to treat the side effects. 

Prescribing information mentioned in this episode:
Elahere (mirvetuximab soravtansine-gynx)
Tivdak (tisotumab vedotin-tftv)

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

CME Information

Release: October 5, 2023; expires October 5, 2026

Financial Disclosures:
Planner/Faculty: Dr. Young reports no relevant financial disclosures.
Faculty: Drs. Berkenstock, Dalvin, and Kim report no relevant financial disclosures.
Review Panel: Dr. Mazeyar Saboori receives consulting and lecture fees from Aerie Pharmaceuticals. The following reviewers report no financial disclosures: Jeffrey D. Henderer, MD; Danah Albreiki, MBBS; Ashiyani Nariani, MD, MPH; Annie Moreau, MD; and Allison Umfress, MD.

Learning Objective: Upon completion of this episode, the listener should be able to describe how antibody-drug conjugates affect the eye and how to screen for and treat potential ocular side effects.

Audience: This activity is intended for comprehensive ophthalmologists.

Accreditation: The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Academy of Ophthalmology designates this internet enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hardware/Software Requirements: This learning activity requires a current web browser and speaker or headset capable of playing streaming audio.